Advancing First-Line Therapy for Multiple Myeloma: Updates From IsKia and IMROZ Trials
August 5th 2025Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity rates by approximately 10% at both the 10–5 and 10–6 levels, particularly benefiting high-risk patients.
PERSEUS and ADVANCE Updates: Evolving Approaches to MRD-Driven Myeloma Care
August 5th 2025Panelists discuss how the PERSEUS trial’s subgroup analysis reinforced that sustained minimal residual disease negativity predicts better long-term outcomes and demonstrated the potential for treatment de-escalation at the 2-year mark, while other trials like Advance showed dramatic increases in MRD negativity rates with quadruplet therapy.
Key Takeaways From CEPHEUS: Subgroup Analysis
July 29th 2025Panelists discuss how emerging evidence from first-line therapy trials continues to demonstrate the superiority of quadruplet over triplet regimens, with the CEPHEUS subgroup analysis confirming that even higher-risk and less-fit patients can benefit from 4-drug combinations while maintaining acceptable safety profiles.
Expert Perspectives on Balancing QOL, Convenience, and Depth of Treatment Response
July 29th 2025Panelists discuss how quality of life (QOL) and treatment convenience should be balanced with maximal depth of response through personalized therapy approaches, emphasizing the importance of multidisciplinary care teams and the flexibility to adapt treatment regimens based on individual patient preferences and circumstances.
Therapy Selection and Management Strategies for Transplant-Ineligible Older Patients
July 22nd 2025Panelists discuss how newer immune-based therapies and bispecific antibodies may enable fixed-duration treatment approaches that could eliminate the need for stem cell transplant in older but fit patients, potentially allowing for treatment-free intervals after achieving deep responses.
Balancing Deeper Response and MRD Negativity With Toxicity Risks in Clinical Decision-Making
July 22nd 2025Panelists discuss how to balance achieving deeper MRD-negative responses against increased toxicity risks in transplant-ineligible patients by personalizing therapy through dose modifications, weekly vs twice-weekly dosing schedules, and careful monitoring while maintaining treatment intensity similar to clinical trials.
Navigating First-Line Therapy Guidelines and Treatment Considerations in High-Risk Cytogenetics
July 15th 2025Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for personalized treatment strategies that consider individual patient frailty and high-risk genetics rather than applying uniform approaches across all older patients.
Managing Early Relapse in Transplant-Eligible MM and the Influence of Clonal Evolution
July 8th 2025Panelists discuss how early relapse in standard-risk patients represents a failure of current risk assessment methods and may require advanced sequencing technologies to identify hidden high-risk features that traditional fluorescence in situ hybridization testing misses.
Balancing Timing of ASCT: Insights on Delayed Transplantation and Long-Term Treatment Outcomes
June 27th 2025Panelists discuss how autologous stem cell transplant (ASCT) deferral should be approached cautiously with concrete medical reasons, as transplant continues to provide superior progression-free survival and potentially curative outcomes for a subset of patients.
Tailoring Maintenance Therapy by Patient Risk: Lenalidomide Alone vs Combination Approaches
June 27th 2025Panelists discuss how maintenance therapy should be tailored based on risk profiles, with standard-risk patients receiving single-agent lenalidomide while high-risk patients may benefit from combination maintenance strategies to achieve more durable responses.
The Role of MRD Status in Post-ASCT Treatment Decisions and Clinical Integration
June 20th 2025Panelists discuss how minimal residual disease (MRD) status can guide post-transplant treatment decisions, particularly for high-risk patients who don’t achieve MRD negativity and patients considering discontinuation of long-term maintenance therapy.
Evaluating First-Line Treatment Options: Quadruplet vs Triplet Regimens and NCCN Guidelines
June 20th 2025Panelists discuss how quadruplet regimens show improved efficacy over triplet regimens without significantly increased safety concerns, with anti-CD38 antibodies being well tolerated and NCCN guidelines now recommending 4-drug regimens for transplant-eligible patients.
Treatment Approaches and Goals: Transplant-Eligible vs. Transplant-Ineligible Patients
June 13th 2025Panelists discuss how treatment strategies differ between transplant-eligible and transplant-ineligible multiple myeloma patients, with transplant eligibility determined by functional status rather than age alone, and how quadruple therapy regimens are increasingly used for transplant-eligible patients to achieve deep, durable responses.